The Wrong Dose Harms Patients

As Doctors, we seek the best care for our patients, but current practice dictates dosing regimens that are either ineffective or toxic to our patients. It’s time to change our approach to treating patients.

MyCare Oncology addresses these current practices in dosing through a new, efficacious form of delivery that provides physicians and caregivers with a full, accurate measure of the patient’s individual dosage requirements.

Clinical Studies

IMATINIB CLINICAL STUDY

Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia

In this study sixty-five percent of CML patients had imatinib levels below the established therapeutic threshold (Cmin or Ctrough). Measuring patient’s Cmin and adjusting dosage resulted in significantly higher imatinib plasma levels and major molecular responses (63%) compared to standard management for patients below the Cmin target (37%). The magnitude of major molecular response with dose adjustment is comparable to that reported for second generation tyrosine kinase inhibitors.

5-FLUOROURACIL CLINICAL STUDY

Reduced Toxicity + Better Outcomes

Blood level guided dose adjustment is a practical approach to personalizing 5-FU dosing. Numerous studies have shown that body surface area based dosing results in the majority of patients underdosed or overdosed. In this study, the majority of patients in all clinical colorectal cancer regimens were underdosed (64%). However, it was possible to adjust patients’ doses to achieve optimal 5-FU blood levels. This study validated 5-FU dose adjustment in a clinical setting:

• Dose adjustment was successful in bringing patients into the target range for 5-FU
• Dose adjustment recommendations were practical.
• Patients were administered higher doses to increase exposure.
• The higher dose intensity did NOT result in an unacceptable increase in the incidence of toxicities

PACLITAXEL CLINICAL STUDY

TDM of Paclitaxel Reduces Severe Toxicity and Maintains Efficacy

Neutropenia and neuropathy can be serious side-effects associated with paclitaxel chemotherapy. While hematological toxicities can be addressed, there is no good solution for chemotherapy induced peripheral neuropathy, which is frequent, may be debilitating and can persist or appear after treatment. One of the largest randomized TDM studies ever demonstrated the potential of paclitaxel dose optimization to:

  • Reduce neuropathy
  • Reduce neutropenia
  • Without impacting survival
DOCETAXEL CLINICAL STUDY

Docetaxel Pharmacokinetics Predicts Neutropenia and Outcomes

The docetaxel pharmacokinetic parameter Area Under the Curve (AUC) was associated with neutropenia and time to progression in non-small cell lung cancer patients.

Clinical Support

FINDINGS

Lorem ipsum dolor sit amet: consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem ipsum dolor sit amet: consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem ipsum dolor sit amet: consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Lorem ipsum dolor sit amet: consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Have Technical Questions?

Start typing and press Enter to search